HIV initially represented death as it was a difficult disease to treat. However, this has changed over the years as some medications have allowed it to be a treatable disease and it can be controlled.
According to the printed journal of Medicine and Public Health, the former president of the Association of HIV-Treating Doctors of Puerto Rico Villamary Rosa assured that, for three decades, HIV medications have undergone changes to improve the lives of patients.
The specialist explained “HIV was initially a virus without treatment that triggered the death of patients when they did not know an effective treatment. Currently the virus is treatable, so much so that some of the drugs that are being developed can be identified as a functional cure, since they reduce or eliminate viral reserves in patients with HIV “
Here you will find a journey through the history of recently approved drugs, those that are under approval or have completed stage three of development.
Recently Approved Drugs
Doravirine (Pifeltro) approved in August 2018, is an NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitor) this drug is for daily use, its dose is once a day and can be consumed with or without food.
Dovato was approved in April 2019, this drug is an integrated combination of Dolutegravir with NRTI.
Ibalizumab was approved in March 2018, this was the first monoclonal antibody to treat HIV positive patients
Drugs that have completed stage 3
Cabotegravir / RilpivirineLA approved on April 29, 2019 by Viiv healthcare, this drug was submitted for approval, more than 90% of its pressure was reported in them.
Cabotegravir is a second generation inhibitor that has been developed in two presentations, table and injectable, the oral form is intended to be used before the injectable.
Fostemsavir- is an anchor inhibitor. This drug is active for almost all subtypes of HIV.
Phase 3 development compounds
Leronlimab-EAB this drug has been in development for over a decade but is currently on the fast track of approval due to the potential it has, it has also been viewed as a drug of change, after a patient has been in depression with oral medications .
UB-421mAb is a monoclonal antibody with a high neutralizing spectrum for the patient.
These drugs make a difference for HIV patients today who have it and are more likely to successfully emerge from this disease.